Key result
Bariatric surgery sustains long-term metabolic syndrome improvements, cutting fasting blood glucose by up to ~45 mg/dL.
Why the study?
Bariatric surgery has known short- and medium-term benefits on metabolic syndrome components, but its long-term impact remains incompletely characterized.
Does bariatric surgery improve long-term metabolic syndrome components in patients?
Meta-Analysis (n=37,840)
Does bariatric surgery improve long-term metabolic syndrome components in patients?
Effect estimate: Pooled estimates ranged from -22.97 to -44.68 mg/dL for FBG, +10.25 to +11.94 mg/dL for HDL, -54.11 to -59.59 mg/dL for TG, -20.55 cm for WC, -7.82 to -9.76 mmHg for SBP, and -4.80 to -6.48 mmHg for DBP
Bariatric surgery provides sustained, long-term (≥ 5 years) improvements in all major metabolic syndrome components, though evidence is primarily based on Roux-en-Y gastric bypass.
Sustained MetS improvements ≥5 years post-bariatric surgery support long-term referral in eligible patients; extends short-term RCT evidence to durable outcomes.
Bariatric surgery (BS) has short- and medium-term benefits in improving metabolic syndrome (MetS) components, but its long-term impact remains incompletely characterized. This systematic review and meta-analysis aimed to quantify the long-term effects of BS (≥ 5 years) on fasting blood glucose (FBG), HDL cholesterol, triglycerides (TG), waist circumference (WC), and systolic and diastolic blood pressure (SBP and DBP). A comprehensive literature search was conducted across relevant databases. Eligible studies included randomized controlled trials and observational cohorts reporting pre- and postsurgical metabolic outcomes after at least 5 years of follow-up. Random-effects meta-analyses and meta-regressions were performed. Fifty-four articles (49 cohorts and five RCTs), including 37,840 baseline participants, were analyzed. BS was associated with significant improvements across all outcomes, with effect sizes varying by study design. Pooled estimates ranged from -22.97 to -44.68 mg/dL for FBG, +10.25 to +11.94 mg/dL for HDL, -54.11 to -59.59 mg/dL for TG, -20.55 cm for WC, -7.82 to -9.76 mmHg for SBP, and -4.80 to -6.48 mmHg for DBP. Meta-regression showed stronger effects in patients with higher baseline values. BS provides sustained, long-term improvements in all major MetS components. However, these findings are primarily driven by studies on Roux-en-Y gastric bypass, whereas long-term data on sleeve gastrectomy remain limited. High-quality longitudinal evidence on sleeve gastrectomy is needed to improve the generalizability of these results to contemporary surgical practice.
No takes yet. Share an insight, caveat, or question.
Barboza et al. (2026) conducted a meta-analysis in Metabolic syndrome components (n=37,840). Bariatric surgery was evaluated on Fasting blood glucose, HDL cholesterol, triglycerides, waist circumference, and systolic and diastolic blood pressure (Pooled estimates ranged from -22.97 to -44.68 mg/dL for FBG, +10.25 to +11.94 mg/dL for HDL, -54.11 to -59.59 mg/dL for TG, -20.55 cm for WC, -7.82 to -9.76 mmHg for SBP, and -4.80 to -6.48 mmHg for DBP). Bariatric surgery provided sustained long-term improvements (≥5 years) in metabolic syndrome components, including fasting blood glucose reductions of 22.97 to 44.68 mg/dL.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: